You are here

Astellas

FDA starts review of Padcev/Keytruda for bladder cancer

FDA starts review of Padcev/Keytruda for bladder cancer

Pharmaphorum

priority review

Flag link:

Astellas builds case for menopause drug fezolinetant

Astellas builds case for menopause drug fezolinetant

Pharmaphorum

Flag link:

Xtandi cleared by FDA for earlier-stage prostate cancer

Xtandi cleared by FDA for earlier-stage prostate cancer

Pharmaphorum

prostate cancer

Flag link:

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Fierce Biotech

Propella Therapeutics

prostate cancer

Flag link:

Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths

Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths

BioSpace

X-linked myotubular myopathy

Flag link:

Astellas’ Izervay reduces GA lesion growth in Phase III trial

Astellas’ Izervay reduces GA lesion growth in Phase III trial

Clinical Trials Arena

geographic atrophy

age-related macular degeneration

clinical trials

Flag link:

A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges

A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges

Forbes

Flag link:

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

Fierce Pharma

Flag link:

Astellas rolls out national Veozah campaign for treating menopause symptoms

Astellas rolls out national Veozah campaign for treating menopause symptoms

Medical Marketing and Media

Flag link:

Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study

Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study

BioSpace

clinical trials

Duchenne Muscular Dystrophy

Flag link:

Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?

Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?

BioSpace

Inflation Reduction Act

Flag link:

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

BioSpace

urothelial cancer

clinical trials

Flag link:

Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial

Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial

Fierce Biotech

Taysha Gene Therapies

Flag link:

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy

PR Newswire

clinical trials

geographic atrophy

Flag link:

EU clears review of Xtandi in earlier-stage prostate cancer

EU clears review of Xtandi in earlier-stage prostate cancer

Pharmaphorum

prostate cancer

Flag link:

Astellas withdraws lawsuit challenging Medicare drug price negotiation plans

Astellas withdraws lawsuit challenging Medicare drug price negotiation plans

Reuters

prostate cancer

Inflation Reduction Act

Flag link:

The 10 drugs that CMS might wrangle into negotiations

The 10 drugs that CMS might wrangle into negotiations

Beckers Hospital Review

Bristol Myers Squibb

Boehringer Ingelheim

Flag link:

Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood

Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood

PR Newswire

Flag link:

Iveric drug approved for type of vision loss as rival’s safety draws scrutiny

Iveric drug approved for type of vision loss as rival’s safety draws scrutiny

BioPharma Dive

geographic atrophy

Flag link:

Pages